135 related articles for article (PubMed ID: 12826150)
1. Calcineurin-free protocols with basiliximab induction allow patients included in "old to old" programs achieve standard kidney transplant function.
Emparan C; Laukötter M; Wolters H; Dame C; Heidenreich S; Senninger N
Transplant Proc; 2003 Jun; 35(4):1326-7. PubMed ID: 12826150
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of calcineurin-free protocols with basiliximab induction in "old-to-old" programs.
Emparan C; Wolters H; Laukötter M; Senninger N
Transplant Proc; 2004 Nov; 36(9):2646-8. PubMed ID: 15621113
[TBL] [Abstract][Full Text] [Related]
3. Use of basiliximab with mycophenolate mofetil in kidney transplantation.
Baron PW; Weissman J; Ojogho ON; Sahney S; Cutler D; James S; Oculam C; Abdelhalim F; Nehlsen-Cannarella SL; Teichman S; Concepcion W
Transplant Proc; 2003 Dec; 35(8):2881-4. PubMed ID: 14697927
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial.
Arbogast HP; Hoffmann JN; Illner WD; Hillebrand GF; Fischereder M; Jauch KW; Land W
Transplant Proc; 2009; 41(6):2529-32. PubMed ID: 19715968
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of basixilimab induction and calcineurin-sparing protocols in "old to old" programs using Markov models.
Emparan C; Wolters H; Laukötter M; Dame C; Senninger N
Transplant Proc; 2003 Jun; 35(4):1324-5. PubMed ID: 12826149
[TBL] [Abstract][Full Text] [Related]
6. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
[TBL] [Abstract][Full Text] [Related]
7. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
8. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of basiliximab induction in "old-to-old" kidney transplant programs: Bayesian estimation, simulation, and uncertainty analysis.
Emparan C; Wolters H; Laukötte M; Senninger N
Transplant Proc; 2005 Jun; 37(5):2069-71. PubMed ID: 15964341
[TBL] [Abstract][Full Text] [Related]
10. Induction with basiliximab in renal transplantation.
Ferrer F; Machado S; Alves R; Macário F; Bastos C; Roseiro A; Mota A
Transplant Proc; 2010 Mar; 42(2):467-70. PubMed ID: 20304166
[TBL] [Abstract][Full Text] [Related]
11. Recovery of graft function in pediatric kidney transplantation is not affected by delayed introduction of cyclosporine.
Cransberg K; Bouts AH; Cornelissen EA; Lilien MR; Van Hoeck KJ; Hop WC; Nauta J
Transplantation; 2008 Nov; 86(9):1199-205. PubMed ID: 19005400
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB
Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
[TBL] [Abstract][Full Text] [Related]
13. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
Tan J; Yang S; Wu W
Transplant Proc; 2005 Mar; 37(2):903-5. PubMed ID: 15848570
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
15. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.
Lebranchu Y; Bridoux F; Büchler M; Le Meur Y; Etienne I; Toupance O; Hurault de Ligny B; Touchard G; Moulin B; Le Pogamp P; Reigneau O; Guignard M; Rifle G
Am J Transplant; 2002 Jan; 2(1):48-56. PubMed ID: 12095056
[TBL] [Abstract][Full Text] [Related]
16. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression.
Gavela Martínez E; Avila Bernabeu AI; Sancho Calabuig A; Beltrán Catalán S; Escudero Quesada V; Pallardó Mateu LM
Transplant Proc; 2009; 41(6):2337-8. PubMed ID: 19715913
[TBL] [Abstract][Full Text] [Related]
17. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
[TBL] [Abstract][Full Text] [Related]
18. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids.
Mourad G; Rostaing L; Legendre C; Garrigue V; Thervet E; Durand D
Transplantation; 2004 Aug; 78(4):584-90. PubMed ID: 15446319
[TBL] [Abstract][Full Text] [Related]
19. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function.
Hong JC; Kahan BD
Transplantation; 2001 May; 71(9):1320-8. PubMed ID: 11397971
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
Teraoka S; Sato S; Sekijima M; Iwado K; Urashima Y; Kudo S; Kai K; Koyama I; Tojinbara T; Nakajima I; Fuchinoue S
Transplant Proc; 2005 Mar; 37(2):791-4. PubMed ID: 15848533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
